Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products

Biologicals

Volumn 28, Issue 1, 2000, Pages 29-32

  Roberts, Peter ^a  

^a BIO PRODUCTS LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DETERGENT; POLYSORBATE 80; REPLENATE; REPLENINE; SOLVENT; TRIBUTYL PHOSPHATE; TRITON X 100;

ANIMAL CELL; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; SINDBIS VIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS RESISTANCE;

ALPHAVIRUS; ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; SEMLIKI FOREST VIRUS; SINDBIS VIRUS; VACCINIA; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 0034003693     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1999.0236     Document Type: Article

References (15)

1. Burnouf T. Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates. Biologicals. 20:1992;91-100.
2. Foster PR, Cuthbertson B. Procedures for the prevention of virus transmission by blood products. Madhok R, Forbes D, Evatt BL. Blood, Blood Products and HIV. 1994;207-248 Chapman and Hall, London.
3. Roberts P. Virological safety of the purified factor IX concentrate, Replenine. Haemophilia. 1:1995;19-22.
4. Horowitz B, Prince AM, Horowitz MS, Watklevicz C. Virus safety of solvent-detergent treated blood products. Brown F. Virological Safety Aspects of Plasma Derivatives. Dev. Biol. Stand. 1993;147-161 Karger, Basel.
5. Horowitz B, Weibe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combinations. Transfusion. 25:1985;516-522.
6. Prince AM, Horowitz B, Brotman B. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri-(n-butyl) phosphate and sodium cholate. Lancet. i:1986;706-710.
7. Prince AM, Horowitz B, Brotman B, Huima T, Richardson L, van der Ende MC. Inactivation of hepatitis B and Hutchinson strain non-A, non-B viruses by exposure to Tween 80 and ether. Vox Sang. 46:1984;36-43.
8. Griffith MJ. Ultrapure plasma factor VIII produced by anti-FVIIIc immunoaffinity chromatography and solvent/detergent viral inactivation. Characterisation of the method M process and Hemofil M antihemophilic factor (human). Ann Hematol. 63:1991;131-137.
9. Feldman PA. Development and characterisation of the high purity factor IX, Replenine. Haemophilia. 1:1995;12-15.
10. Roberts PL. Virus safety of plasma products. Rev Med Vir. 6:1996;25-38.
11. Roberts PL, McAuley A, Dunkerley C, Winkelman L. Virus inactivation during severe heat treatment of a lyophilised factor VIII concentrate. Thromb Haemost. 65:1991;1163.
12. Winkelman, L, Feldman, PA, Evans, DR, Severe heat-treatment of lyophilised coagulation factors, Virus Inactivation in Plasma Products. Curr. Stud. Hematol. Blood Transfusion, 56, J-J, Morgenthaler, 56, 69, Karger, Basel.
13. Franki RIB, Fauquet CM, Knudson DL, Brown F. Classification and nomenclature of viruses. 1991;Springer-Verlag, Vienna.
14. Fenner F, Wittek R, Dumbell KR. The Orthopoxviruses. 1989;Academic Press, San Diego.
15. Moss B. Poxviridae: The viruses and their replication. Fields BN, Knipe DM, Howley PM. Fields Virology, 3rd edition. 1996;2637-2671 Lippincott-Raven, Philadelphia.